Trials / Conditions / Relapsed or Refractory Hematologic Malignancies
Relapsed or Refractory Hematologic Malignancies
6 registered clinical trials studyying Relapsed or Refractory Hematologic Malignancies — 5 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Not Yet Recruiting | Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies NCT07485504 | Tcelltech Inc. | Phase 1 |
| Recruiting | A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies NCT07173595 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies NCT07107204 | Biotroy Therapeutics | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies NCT06252298 | Sinocelltech Ltd. | Phase 1 |
| Completed | Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia NCT04926285 | University of Illinois at Chicago | Phase 1 |
| Recruiting | Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies NCT03838926 | Vanda Pharmaceuticals | Phase 1 |